Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
rituximab + bendamustine
- Development stage
- Unknown
- Lead developer
- Teva Pharmaceutical
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Subcutaneous
01
Overview
Rituximab + bendamustine is a combination chemotherapy regimen used primarily for the treatment of indolent CD20-positive non-Hodgkin’s lymphoma and mantle cell lymphoma. Rituximab is a monoclonal antibody that targets the CD20 antigen on B lymphocytes, leading to their destruction through immune-mediated mechanisms. Bendamustine is an alkylating agent that causes DNA cross-linking and damage, resulting in cancer cell death. The combination has demonstrated efficacy as both first-line and relapsed/refractory therapy, with improved progression-free survival compared to some older regimens and generally favorable tolerability[3][5][6][8].
- Brand names
- TreandaBendekaBelrapzoRituxanMabThera
- Other names
- Benda-R regimenBR regimen
02
Targets
Beyond the preview
Go deeper on rituximab + bendamustine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on rituximab + bendamustine.